New Anatomy-Based Framework Targets Prevention of GLP-1 RA-Associated Facial Aging

Key Takeaways

• A new conceptual framework proposes anatomy-based risk stratification to identify patients at higher risk for GLP-1 receptor agonist-associated facial volume loss.
• The model introduces a 4-phase prevention algorithm aligned with weight-loss kinetics and emphasizes early intervention rather than late-stage correction.
• The authors stress that the framework is hypothesis-generating and requires prospective validation before routine clinical adoption.

A conceptual model published online ahead of print in Aesthetic Plastic Surgery proposes an anatomy-driven approach to identifying and preventing facial aging changes associated with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, commonly referred to as “Ozempic face.”

The authors address a growing aesthetic concern accompanying the widespread use of GLP-1 RAs for obesity and metabolic disease management. According to the authors, current discussions surrounding GLP-1 RA-associated facial changes have largely focused on describing volume loss patterns and correcting established deficits rather than preventing them.

Anatomy-Based Framework Aims to Prevent “Ozempic Face” Before Significant Volume Loss Occurs

Drawing on facial aging biomechanics, emerging literature regarding GLP-1 RA-associated facial changes, and clinical pattern recognition, the authors developed a hypothesis-generating risk-stratification framework based on anatomical phenotype. The model is designed to identify patients who may be more susceptible to rapid, region-specific facial volume loss during weight reduction.

The proposed framework incorporates a 4-phase prevention algorithm that aligns clinical interventions with weight-loss kinetics. Components include early preventive measures, patient-specific modifiers, and clinical “off-ramps” intended to guide management before significant facial aging changes become apparent.

Rather than positioning facial volume loss as an inevitable consequence of successful weight reduction, the authors advocate for anticipatory management strategies tailored to individual anatomy and treatment trajectories. The goal is to shift clinical thinking from reactive correction toward proactive prevention.

The authors emphasized that the framework remains conceptual and has not yet undergone prospective validation. Further research will be needed to determine its predictive accuracy, clinical utility, and role in aesthetic treatment planning for patients receiving GLP-1 RA therapy.

“This conceptual model proposes a shift from reactive correction to preventive, anatomy-based management of GLP-1 RAs-associated facial changes,” the authors wrote. “Future studies are needed to validate and refine this framework.”

Source

Preventing GLP-1-Associated Facial Aging: An Anatomy-Driven Risk Stratification Model and Prevention Algorithm in the "Ozempic Face" Era. Aesthetic Plast Surg. Published online June 8, 2026. doi:10.1007/s00266-026-05953-6.